Treatment of Morton neuroma with botulinum toxin a: A pilot study

Clinical Drug Investigation

Volumn 33, Issue 7, 2013, Pages 497-503

  Climent, José M ^a   Mondéjar Gómez, Francisco ^b   Rodríguez Ruiz, Carmen ^c   Díaz Llopis, Ismael ^a   Gómez Gallego, Diego ^a   Martín Medina, Patricia ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Virgen Del Castillo Hospital   (Spain)

^c USP Hospital San Jaime   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CORTICOSTEROID;

ABSENCE OF SIDE EFFECTS; ADULT; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG EFFICACY; FEMALE; FOOT; FOOT HEALTH STATUS QUESTIONNAIRE; FUNCTIONAL STATUS; HUMAN; MALE; METATARSALGIA; MORTON NEUROMA; NEUROMA; OPEN STUDY; PAIN ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SELF REPORT; SINGLE DRUG DOSE; STANDING; TREATMENT RESPONSE; VISUAL ANALOG SCALE; WALKING;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMA; PILOT PROJECTS;

EID: 84879803574     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0090-0     Document Type: Review

References (47)

1. Hassouna H, Singh D. Morton's metatarsalgia: pathogenesis, aetiology and current management. Acta Orthop Belg. 2005;71(6):646-55.
2. Bennett GL, Graham CE, Mauldin DM. Morton's interdigital neuroma: a comprehensive treatment protocol. Foot Ankle Int. 1995;16:760-3.
3. Sofka CM, Adler RS, Ciavarra GA, et al. Ultrasound-guided interdigital neuroma injections: short-term clinical outcomes after a single percutaneous injection: preliminary results. HSS J. 2007;3(1):44-9.
4. Zanetti M, Weishaupt D. MR imaging of the forefoot: Morton neuroma and differential diagnoses. Semin Musculoskelet Radiol. 2005;9(3):175-86.
5. Thomson CE, Gibson JN, Martin D. Interventions for the treatment of Morton's neuroma. Cochrane Database Syst Rev. 2004;(3):CD003118.
6. Greenfield J, Rea J Jr, et al. Morton's interdigital neuroma. Indications for treatment by local surgery. Clin Orthop Relat Res. 1984;185:142-4.
7. Morton TG. The classic. A peculiar and painful affection of the fourth metatarso-phalangeal articulation. Thomas G. Morton, M.D. Clin Orthop Relat Res. 1979;142:4-9.
8. Pasero G, Marson P. Filippo Civinini (1805-1844) and the discovery of plantar neuroma [in Italian]. Reumatismo. 2006;58(4):319-22.
9. Lee MJ, Kim S, Huh YM, et al. Morton neuroma: evaluated with ultrasonography and MR imaging. Korean J Radiol. 2007;8(2):148-55.
10. Saygi B, Yildirim Y, Saygi EK, et al. Morton's neuroma: comparative results of two conservative methods. Foot Ankle Int. 2005;26:556-9.
11. Dockery GL. The treatment of intermetatarsal neuromas with 4% alcohol sclerosing injections. J Foot Ankle Surg. 1999;38:403-8.
12. Singh SK, Ioli JP, Chiodo CP. The surgical treatment of Morton's neuroma. Curr Orthop. 2005;19:379-84.
13. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve. 1997;Suppl 6:146-68.
14. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2004;(4):CD004315.
15. Jabbari B, Machado D. Treatment of refractory pain with botulinum toxins: an evidence-based review. Pain Med. 2011;12(11):1594-606.
16. Lipton RB, Varon SF, Grosberg B, et al. Onabotulinum toxin A improves quality of life and reduces impact of chronic migraine. Neurology. 2011;77(15):1465-72.
17. Díaz-Llopis IV, Rodriguez-Ruiz CM, Mulet-Perry S, et al. Randomized controlled study of the efficacy of the injection of botulinum toxin type A versus corticosteroids in chronic plantar fasciitis: results at one and six months. Clin Rehabil. 2012;26(7):594-606.
18. Argoff C. The emerging use of botulinum toxins for the treatment of neuropathic pain. Pain Med. 2010;11(12):1750-2.
19. Ranoux D. Botulinum toxin and peripheral neuropathies: what should be expected? Rev Neurol (Paris). 2011;167(1):46-50.
20. Dworkin RH, O'Connor AB, Audette J. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3-14.
21. Sim WS. Application of botulinum toxin in pain management. Korean J Pain. 2011;24(1):1-6.
22. Ruiz-Huete C, Bermejo PE. Toxina botulínica tipo A en el tratamiento del dolor neuropático en un caso de neuralgia postherpética. Neurología. 2008;23(4):259-62.
23. Tsai CP, Liu CY, Lin KP, et al. Efficacy of botulinum toxin type A in the relief of Carpal tunnel syndrome: a preliminary experience. Clin Drug Investig. 2006;26(9):511-5.
24. Vanelderen P, Lataster A, Levy R, et al. Occipital neuralgia. Pain Pract. 2010;10(2):137-44.
25. Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473-8.
26. Ngeow WC, Nair R. Injection of botulinum toxin type A (Botox) into trigger zone of trigeminal neuralgia as a means to control pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e47-50.
27. Piovesan EJ, Teive HG, Kowacs PA, et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology. 2005;65:1306-8.
28. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005;26(5):785-93.
29. Sirera-Vercher MJ, Sáez-Zamora P, Sanz-Amaro MD. Traducción y adaptación transcultural al castellano y al valenciano del Foot Health Status Questionnaire. Rev Esp Cir Ortop Traumatol. 2010;54(4):211-9.
30. Bennett PJ, Patterson C, Wearing S, et al. Development and validation of a questionnaire designed to measure foot-health status. J Am Podiatr Med Assoc. 1998;88:419-28.
31. Hassouna H, Singh D, Taylor H, et al. Ultrasound guided steroid injection in the treatment of interdigital neuralgia. Acta Orthop Belg. 2007;73(2):224-9.
32. Markovic M, Crichton K, Read JW, et al. Effectiveness of ultrasound-guided corticosteroid injection in the treatment of Morton's neuroma. Foot Ankle Int. 2008;29(5):483-7.
33. Mozena JD, Clifford JT. Efficacy of chemical neurolysis for the treatment of interdigital nerve compression of the foot: a retrospective study. J Am Podiatr Med Assoc. 2007;97(3):203-6.
34. Magnan B, Marangon A, Frigo A, et al. Local phenol injection in the treatment of interdigital neuritis of the foot (Morton's neuroma). Chir Organi Mov. 2005;90(4):371-7.
35. Fanucci E, Masala S, Fabiano S, et al. Treatment of intermetatarsal Morton's neuroma with alcohol injection under US guide: 10-month follow-up. Eur Radiol. 2004;14(3):514-8.
36. Hughes RJ, Ali K, Jones H, et al. Treatment of Morton's neuroma with alcohol injection under sonographic guidance: follow-up of 101 cases. Am J Roentgenol. 2007;188(6):1535-9.
37. Wu H, Sultana R, Taylor KB, et al. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection versus Lidocaine/Depomedrol injection on residual and phantom limb pain: initial report. Clin J Pain. 2012;28(2):108-12.
38. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord. 2011;17(Suppl 1):28-33.
39. Acquadro MA, Borodic GE. Treatment of myofascial pain with botulinum A toxin [letter]. Anesthesiology. 1994;80:705-6.
40. Cheshire WP, Abashian SW, Mann JD. Botulinum toxin in the treatment of myofascial pain syndrome. Pain. 1994;59:65-9.
41. Kuan T-S, Chen J-T, Chen S-M, Chien C-H, Hong C-Z. Effect of botulinum toxin on endplate noise in myofascial trigger spots of rabbit skeletal muscle. Am J Phys Med Rehabil. 2002;81:512-20.
42. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blinded placebo-controlled multicentre study. Pain. 2006;125(1-2):82-8.
43. Wheeler AH, Goolkasian P, Gretz SS. A randomized, double-blind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine. 1998;23:1662-7.
44. Yue SK. Initial experience in the use of botulinum toxin A for the treatment of myofascial related muscle dysfunctions. J Musculoskelet Pain. 1995;3(Suppl 1):22.
45. Kapural L, Stillman M, Kapural M, et al. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: a case series. Pain Pract. 2007;7(4):337-40.
46. Tilton AH. Injectable neuromuscular blockade in the treatment of spasticity and movement disorders. J Child Neurol. 2003;18(Suppl 1):S50-66.
47. Compérat E, Reitz A, Delcourt A, Capron F, Denys P, Chartier-Kastler E. Histologic features in the urinary bladder wall affected from neurogenic overactivity: a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A. Eur Urol. 2006;50(5):1058-64.